摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲氧基乙基肼盐酸盐 | 3044-15-3

中文名称
2-甲氧基乙基肼盐酸盐
中文别名
肼,(2-甲氧基乙基)-
英文名称
(2-methoxyethyl)hydrazine
英文别名
2-methoxyethylhydrazine
2-甲氧基乙基肼盐酸盐化学式
CAS
3044-15-3
化学式
C3H10N2O
mdl
MFCD09813208
分子量
90.1252
InChiKey
IBELBRDFPCFICX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    84-90 °C(Press: 56 Torr)
  • 密度:
    0.929±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    6
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    47.3
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2928000090

SDS

SDS:cb3442fc7932dd4badb1ca5cfd7bb477
查看

反应信息

  • 作为反应物:
    描述:
    2-甲氧基乙基肼盐酸盐亚硝酸丁酯sodium ethanolate 作用下, 生成 (E)-methoxyethanediazoate
    参考文献:
    名称:
    Rate-Limiting Formation of Diazonium Ions in the Aqueous Decomposition of Primary Alkanediazoates
    摘要:
    Rate constants, k(0), for the buffer-independent decomposition of four primary (E)-alkanediazoates and one primary (Z)-alkanediazoate in aqueous media at 25 degrees C, ionic strength 1 M (NaClO4) are reported. Between pH 4 and 12 the plot of log k(0) against pH is biphasic with a hydrogen ion-dependent reaction at the high-pH end changing to a pH-independent region at lower pH. The change in absorbance at 235 nm of the relatively stable (E)-trifluoroethanediazoate as a function of pH gives a good fit to a simple titration curve for a monofunctional acid with pK(a) = 7.00 +/- 0.04 that is in good agreement with the kinetic pK(a) determined from the pH-rate profile between pH 4 and 12. The plot of log k(1), the pH-independent rate constant, against sigma* for the primary (E)-alkanediazoates, and (E)-methane- and (E)-2-butanediazoates previously reported, yields a common line with a slope rho* = -4.4. Of the 1-butanol formed from the decomposition of (E)-1-butanediazoate in D2O at pH(obs),b, = 10.50, 6% contains deuterium, while, of the 1-butanol formed in the presence of 1 M NaOD in D2O, 25% contains deuterium. A total of 96% of the iodotrifluoroethane formed upon decomposition of (E)-trifluoroethanediazoate in a D2O solution that is 1 M in NaI contains at least a single deuterium atom. These data combined with small negative values of Delta S#, normal solvent deuterium isotope effects, and the decreases in k(1) of between 500- and 1000-fold on change of solvent to ethanol are consistent with a mechanism that involves the rate-limiting unassisted heterolytic bond fission of the diazoic acid to yield the diazonium ion. The decomposition of [O-16]-(E)-1-butanediazoate in water containing 47 +/- 2% O-18 yields 1-butanol of which 49 +/- 2% contains O-18. This observation, in combination with the observed pH-dependent deuterium incorporation into 1-butanol during decomposition of (E)-1-butanediazoate, above, indicates that the 1-butanediazonium ion is a diffusionally equilibrated intermediate. The rate constant for the pH-independent decomposition of the (Z)-trifluoroethanediazoate is 2600 times greater than that for the corresponding (E) isomer. The decomposition of the (Z)-trifluoroethanediazoate, but not its (E) isomer, is catalyzed by buffer acids, and the catalysis by carboxylic acids is characterized by a Bronsted plot with a slope alpha = 0.41. Catalysis by methoxylammonium ion is comparatively weak, the rate constant falling a log unit below the aforementioned Bronsted line. The solvent deuterium isotope effect for formic acid catalysis is k(HA)/k(DA) = 3.1 +/- 0.2 It is concluded that the mechanism for general acid catalysis of the decomposition of the (Z)-diazoic acid entails proton transfer to oxygen that is concerted with N-O bond heterolysis to yield the diazonium ion.
    DOI:
    10.1021/ja00094a016
  • 作为产物:
    参考文献:
    名称:
    Gadzhiev,G.Yu.; Kesemenli,S.G., Journal of Organic Chemistry USSR (English Translation), 1972, vol. 8, p. 1849 - 1851
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis and Antihypertensive Activity of 4-(Diazabicyclo[4.1.0]-heptenyloxy)benzopyran Derivatives and Their Analogues.
    作者:Haruhiko HORINO、Tetsuya MIMURA、Katsuji KAGECHIKA、Masahiro OHTA、Hideo KUBO、Masayuki KITAGAWA
    DOI:10.1248/cpb.46.602
    日期:——
    0]hept- 2-en-2-yl)oxy]-2H-1-benzopyrans and their analogues were synthesized and evaluated on potassium channel opening and hypotensive activities. Compound (-)-13B with a (4-methyl-5-oxo-3,4-diazabicyclo[4.1.0]hept-2-en-2-yl)oxy group for the 4-position of the benzopyran ring was 3 times as potent as EMD 57283 (II), the lead compound, in hypotensive activity. The results would demonstrate that 5-oxo-3,4-diazabicyclo[4
    一系列的3,4-二氢-3-羟基-4-[(5-氧代-3,4-二氮杂双环[4.1.0]庚二-2-烯-2-基)氧基] -2H-1-苯并吡喃和合成了它们的类似物,并对钾通道的开放和降压活性进行了评估。对于苯并吡喃环的4-位具有(4-甲基-5-氧代-3,4-二氮杂双环[4.1.0]庚-2-烯-2-基)氧基的化合物(-)-13B为3在降压活动中的功效是主要化合物EMD 57283(II)的两倍。结果表明5-氧代-3,4-二氮杂双环[4.1.0]庚-2-烯-2-基氧基部分作为苯并吡喃型钾通道开放剂的4-位上的取代基是有效的。
  • NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS
    申请人:ITEOS THERAPEUTICS S.A.
    公开号:US20200102319A1
    公开(公告)日:2020-04-02
    The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of Formula (I) for the treatment and/or prevention of proliferative disorders, including cancers.
    本发明涉及式(I)的化合物或其药用可接受盐。该发明进一步涉及将式(I)的化合物用作A2A抑制剂。该发明还涉及将式(I)的化合物用于治疗和/或预防增殖性疾病,包括癌症。
  • 一种选择性NK-3受体拮抗剂及其制备和应用
    申请人:明慧医药(杭州)有限公司
    公开号:CN111825677A
    公开(公告)日:2020-10-27
    本发明提供了一种选择性NK‑3受体拮抗剂及其制备和应用,具体地,本发明提供了一种如下式(I)所示的化合物。所述的化合物对调节细胞因子和/或干扰素具有出乎意料的活性,可用于治疗CNS和外周疾病或病症。
  • Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase
    申请人:Anderson Kevin William
    公开号:US20070225280A1
    公开(公告)日:2007-09-27
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    本文提供了以下式(I)的化合物: 以及其药学上可接受的盐,其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
  • Regioselective Construction and Screening of 1,3-Disubstituted Tetrahydroindazolones in Enantiomerically Pure Pairs
    作者:Heebum Song、Hanjae Lee、Jonghoon Kim、Seung Bum Park
    DOI:10.1021/co200150d
    日期:2012.1.9
    we describe a regioselective synthetic pathway for enantiopure 1,3-disubstituted tetrahydroindazolone derivatives via the condensation of 2-acylcyclohexane-1,3-dione with various alkyl- and arylhydrazines using the steric effects of a Boc-protected pyrrolidine ring. This synthetic method has a broad scope for substrate generality for various hydrazines with excellent regioselectivity. To maximize the
    在本文中,我们通过Boc保护的吡咯烷环的空间效应,通过2-酰基环己烷-1,3-二酮与各种烷基和芳基肼的缩合,描述了对映体纯的1,3-二取代的四氢吲哚酮衍生物的区域选择性合成途径。该合成方法对于各种肼具有优异的区域选择性的底物通用性具有广泛的范围。为了使分子多样性最大化,通过使用溶液相平行合成和聚合物负载的试剂对吡咯烷环的仲胺进行系统的N-修饰,进一步追求1,3-二取代的四氢吲哚并酮的多样化。构建了一个包含总共272种药物样四氢吲哚酮(包括85个对映异构体对)的文库。未经进一步纯化的平均纯度为95%。
查看更多